Dr. Pasi Jänne
MD, PhD
Senior Vice President for Translational Medicine & Senior Physician
corporate_fareDana-Farber Cancer Institute, Boston, USA
Pasi Jänne
MD, PhD
Dr. Pasi A. Jänne, MD, PhD, is a medical oncologist and translational cancer researcher at Dana-Farber Cancer Institute in Boston, USA, where he serves as Senior Vice President for Translational Medicine and Senior Physician. He is Professor of Medicine at Harvard Medical School and holds the David M. Livingston, MD, Chair at Dana-Farber. Dr. Jänne is internationally recognised as one of the co-discoverers of EGFR mutations in lung cancer and a pioneer of precision medicine for non-small cell lung cancer.
With approximately 30 years of experience since completing his MD and PhD at the University of Pennsylvania in 1996, Dr. Jänne has built an internationally recognised career at the intersection of advanced lung cancer care and laboratory-based translational research. He directs the Belfer Center for Applied Cancer Science and the Chen-Huang Center for EGFR Mutant Lung Cancers at Dana-Farber. His research programme focuses on mechanisms of sensitivity and resistance to EGFR-targeted kinase inhibitors, combining genomic, biochemical, and biological studies of patient-derived tumours. He led the phase I clinical trial of osimertinib, which received FDA approval in November 2015, and has led multiple additional clinical studies that have contributed to changes in the standard of care for EGFR-mutant lung cancer. Google Scholar records more than 160,000 citations and an h-index of 177 for his published work.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Dr. Jänne at Dana-Farber Cancer Institute, subject to hospital scheduling and case acceptance.
Why Consider Dr. Pasi A. Jänne?
Dr. Jänne combines an active clinical practice in lung cancer with a translational research programme that has directly shaped how EGFR-mutant non-small cell lung cancer is treated worldwide. Patients with EGFR-mutant lung cancer, drug-resistant disease, or complex thoracic oncology cases may seek his expertise for advanced treatment planning, targeted therapy selection, or specialist second opinion.
Areas of Specialisation
Dr. Jänne's clinical and research practice centres on EGFR-mutant non-small cell lung cancer, targeted therapy, and the biology of kinase inhibitor resistance.
Dr. Jänne's expertise spans medical oncology for thoracic cancers, molecularly guided treatment selection, and translational research connecting laboratory discoveries to clinical care for patients with lung cancer.
EGFR-Mutant Non-Small Cell Lung Cancer
Comprehensive clinical and research expertise in EGFR-driven lung cancer, including treatment selection, resistance mechanisms, and novel therapeutic strategies.
- arrow_rightTreatment planning for EGFR-mutant NSCLC including first-, second-, and third-generation EGFR inhibitors
- arrow_rightClinical evaluation of osimertinib and related EGFR-directed agents
- arrow_rightBiomarker-driven treatment selection based on tumour genomics
- arrow_rightEvaluation and management of acquired resistance to EGFR inhibitors including EGFR T790M and MET amplification
- arrow_rightTranslational studies combining patient-derived tumour samples with laboratory models to identify novel resistance mechanisms
- arrow_rightClinical trial evaluation of agents targeting resistance pathways
Translational Oncology & Precision Medicine
Laboratory and genomic research directly linked to patient care and clinical trial design.
- arrow_rightGenomic and biochemical analysis of patient tumours to identify therapeutic vulnerabilities
- arrow_rightDevelopment of novel EGFR inhibitors and combination targeted therapy strategies
- arrow_rightClinical trials of precision therapies for genomic subtypes of lung cancer
- arrow_rightSystemic treatment planning for non-small cell lung cancer
- arrow_rightMultidisciplinary lung cancer care in the Thoracic Oncology programme at Dana-Farber
- arrow_rightExpert second-opinion consultations for complex or refractory lung cancer cases
Procedures Performed
Clinical services and treatment approaches in thoracic oncology and precision medicine
Dr. Jänne provides medical oncology care for lung cancer patients, including targeted therapy planning, biomarker-guided treatment selection, and clinical trial evaluation, at Dana-Farber Cancer Institute's Thoracic Oncology programme.
Medical Oncology for Lung Cancer
Medical OncologySystemic treatment planning and clinical management for patients with non-small cell lung cancer, including EGFR-mutant and other genomically defined subtypes.
Targeted Therapy & Molecular Oncology
Targeted TherapyBiomarker-driven treatment selection and molecularly guided care for patients with EGFR-mutant and other genomically defined lung cancers.
Clinical Trial Participation
Complex DiseaseActive involvement in phase I–III clinical trials evaluating novel targeted therapies and combination approaches for genomic subtypes of lung cancer.
Second Opinion Consultations
Second OpinionDana-Farber offers an Online Second Opinion Programme for adult patients in the US and internationally, allowing access to expert review without travel to Boston.
Research & Publications
Peer-reviewed contributions and clinical research in lung cancer and precision oncology
Dr. Jänne is among the most cited researchers in precision lung cancer medicine, with over 160,000 citations and an h-index of 177 according to Google Scholar. His research programme at Dana-Farber focuses on EGFR-targeted therapies, mechanisms of kinase inhibitor resistance, and the development of novel therapeutic strategies for genomic subtypes of lung cancer.
Dr. Jänne's full publication list is available on Google Scholar and PubMed. His laboratory at Dana-Farber continues to investigate novel EGFR-directed therapies and resistance mechanisms in lung cancer.
Education & Training
Dr. Jänne completed his MD and PhD at the University of Pennsylvania in 1996, followed by internal medicine residency at Brigham and Women's Hospital and medical oncology fellowship training at Dana-Farber/Partners CancerCare, which he completed in 2001.
Clinical Experience
Dr. Jänne has been based at Dana-Farber Cancer Institute since completing his fellowship in 2001, building his career from clinician-scientist to one of Dana-Farber's most senior physician-scientist leaders in thoracic oncology and translational medicine.
Languages & International
Dr. Jänne consults at Dana-Farber Cancer Institute in English. Additional spoken languages have not been publicly confirmed in official sources.
CancerFax can coordinate professional medical interpreter support for international patients seeking consultation at Dana-Farber Cancer Institute.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Pasi Jänne
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Pasi Jänne's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Pasi Jänne's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Pasi Jänne before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Pasi Jänne's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Pasi Jänne's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Pasi Jänne's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Pasi A. Jänne
Dr. Jänne specialises in lung cancer, particularly non-small cell lung cancer and EGFR-mutant lung cancer. His clinical practice at Dana-Farber Cancer Institute's Thoracic Oncology programme focuses on patients with EGFR-driven thoracic malignancies and related conditions requiring targeted therapy.
Dr. Jänne is based at Dana-Farber Cancer Institute in Boston, Massachusetts, USA. He also holds a faculty appointment as Professor of Medicine at Harvard Medical School.
Dana-Farber Cancer Institute provides services for international patients, including care coordination support. CancerFax can assist in preparing and submitting medical reports for review and help coordinate the next steps with the institution, subject to hospital scheduling and case acceptance.
You can submit your medical reports through CancerFax. The CancerFax team will review the documents, prepare the case for submission, and coordinate the next steps. Dana-Farber also offers an Online Second Opinion Programme that allows patients from across the US and internationally to receive an expert written second opinion without travelling to Boston, subject to specialist availability.
Dr. Jänne is one of the co-discoverers of EGFR mutations in lung cancer and their association with response to EGFR tyrosine kinase inhibitors, co-authoring the landmark 2004 Science paper that helped define the era of precision oncology for lung cancer. He also led the phase I clinical trial of osimertinib, which received FDA approval in November 2015 and became a standard treatment for EGFR-mutant non-small cell lung cancer.
Yes. Dana-Farber states that Dr. Jänne has led multiple clinical trials of targeted therapies for genomic subtypes of lung cancer, including studies that have contributed to improved standards of care. Patients may be evaluated for clinical trial eligibility based on their molecular profile and disease status. Availability is subject to trial status and eligibility criteria.
Connect with Pasi Jänne Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.